Acadia's Q4 earnings miss estimates, but total revenues beat expectations driven by Nuplazid & Daybue

From Nasdaq: 2025-03-04 04:09:00

Acadia Pharmaceuticals (ACAD) reported Q4 2024 earnings of 17 cents per share, missing estimates, with GAAP earnings of 86 cents. Total revenues of $259.6 million beat estimates, driven by sales of Nuplazid and Daybue. In 2024, revenues rose 32% year over year. ACAD expects 2025 revenues to be between $1.030-$1.095 billion. R&D expenses are projected to be $310-$330 million, SG&A expenses between $535-$565 million.

Shares of Acadia have gained 8.7% in the past three months. R&D expenses rose 51% to $100.7 million, while SG&A expenses increased by 17% to $130.1 million. Acadia had cash of $756 million as of Dec. 31, 2024. In 2024, the company recorded adjusted earnings of 48 cents, missing estimates. ACAD expects approval for trofinetide in the EU in Q1 2026.

Acadia updated timelines for its clinical programs and signed an exclusive worldwide license agreement with Saniona for ACP711. The company plans to study ACP711 for essential tremor in 2026. Acadia currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the sector include Gilead Sciences (GILD), BioMarin Pharmaceutical (BMRN), and Amicus Therapeutics (FOLD), each with a Zacks Rank #2 (Buy). GILD and BMRN have shown positive earnings estimates improvements.



Read more at Nasdaq: Acadia’s Q4 Earnings Miss, Nuplazid & Daybue Drive Revenue Growth (Revised)